Pharmacosmos Company Profile

What is the competitive landscape for PHARMACOSMOS

PHARMACOSMOS has two approved drugs.

There are nineteen US patents protecting PHARMACOSMOS drugs.

There are one hundred and ninety-five patent family members on PHARMACOSMOS drugs in thirty-one countries and one supplementary protection certificate in one country.

Summary for Pharmacosmos

International Patents:	195
US Patents:	19
Tradenames:	2
Ingredients:	2
NDAs:	2
Patent Litigation for Pharmacosmos:	See patent lawsuits for Pharmacosmos
PTAB Cases with Pharmacosmos as petitioner:	See PTAB cases with Pharmacosmos as petitioner

Drugs and US Patents for Pharmacosmos

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-003	Jan 16, 2020		RX	Yes	Yes	12,030,962		Y	Y
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-001	Jan 16, 2020		DISCN	Yes	No	11,633,489
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-002	Jan 16, 2020		DISCN	Yes	No	11,851,504		Y	Y
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-002	Jan 16, 2020		DISCN	Yes	No	8,815,301		Y	Y
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	10,189,849			Y
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	10,189,850		Y
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	9,487,530

International Patents for Pharmacosmos Drugs

Country	Patent Number	Estimated Expiration
Spain	3032492
Poland	3156075
Brazil	112019011410
Japan	2018150333
Spain	2592515
China	106008533
Japan	6767456

Supplementary Protection Certificates for Pharmacosmos Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2411053	C02411053/01	Switzerland		PRODUCT NAME: FERRUM (III) UT FERRI ISOMALTOSIDUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67001 26.08.2019

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pharm Assoc
• Pharm Res Assoc
• Pharm Spec
• Pharm Ventures
• Pharma Serve Ny
• Pharmaand
• Pharmacare

Pharmacosmos: Market Position, Strengths & Strategic Insights

Last updated: April 22, 2026

Pharmacosmos specializes in iron deficiency and anemia treatments. Its core offerings include IV iron products, notably the Ferric derisomaltose (FDI), with a focus on large-volume administration and high efficacy. The company maintains a significant position in Europe, particularly in the hospital and nephrology segments and is expanding into the U.S. and other markets through strategic partnerships and regulatory approvals.

---

Key Market Position

Aspect	Details
Market Focus	Iron deficiency anemia, chronic kidney disease (CKD), dialysis patients
Geographic Coverage	Europe (major), North America (expanding), Asia-Pacific (entry phase)
Revenue (2022)	Approx. €250 million (estimated)
Market Share	Estimated 10-15% in European IV iron market, second to FDC/Fresenius
Major Competitors	Vifor Pharma (Fenospan), Pharmaceutics International, FMC Oncology

Pharmacosmos holds a leading or significant share in European hospital IV iron segments with a growing footprint in North America post-FDA approval of FDI in 2022. Its expanding presence is driven by differentiated product attributes and strategic distribution agreements.

---

Strengths

Product Differentiation

• Ferric derisomaltose (FDI): High-dose, single-dose infusion capability reduces treatment sessions, improving patient convenience.
• Safety Profile: Lower incidence of hypersensitivity reactions compared to older iron formulations.
• Stability: Suitable for large-volume infusions, appealing to hospital systems seeking efficient treatment protocols.

Regulatory Strategy

• Success in obtaining CE mark and FDA approval for FDI accelerates market entry.
• Anticipates approvals in Japan and China, leveraging regional partnerships.

Market Penetration

• Established partnerships with hospital groups across Europe.
• Focused on nephrology, an area with high iron deficiency prevalence.
• Investment in clinical trials to expand indications, including inflammatory bowel disease.

Innovation & Pipeline

• Ongoing development of next-generation iron therapies.
• Exploration of fixed-dose regimens and combination treatments for anemia.

---

Strategic Insights

Competitive Advantages

• The ability to administer high-dose iron in a single infusion reduces treatment time and operational costs.
• Strong clinical data supporting improved safety and efficacy.
• Regional focus on markets with high CKD prevalence increases the addressable market.

Challenges & Risks

• Market dominance by established players, such as Vifor Pharma and FDC.
• Regulatory hurdles in entering emerging markets.
• Price pressure from biosimilar and generic formulations.

Opportunities

• Expansion into iron deficiency in oncology and heart failure populations.
• M&A activities to acquire complementary portfolios.
• Collaborations with hospital systems for integrated anemia management.

Threats

• Pricing pressure from payers and healthcare systems.
• Regulatory delays or rejections delaying market access.
• Patent expiry risks for key formulations.

---

Comparative Market Analysis

Company	Key Products	Estimated Market Share	Strengths	Challenges
Pharmacosmos	FDI	10-15% (Europe), growing in North America	Single-dose IV iron, high safety profile	Competition from FDC, biosimilars
Vifor Pharma	Fenospan (Ferinject), Venofer	40-45%	Established brand, extensive distribution	Patent expiry, market consolidation
FDC	Venofer	25-30%	Early market entry, broad established base	Less favorable safety profile, multiple infusions

This competitive environment prioritizes product differentiation, clinical data, and regulatory speed.

---

Strategic Recommendations

• Market Expansion: Accelerate approvals in Asia-Pacific to diversify revenue streams.
• Product Portfolio: Develop or acquire new formulations delivering longer infusion intervals.
• Clinical Trials: Invest in studies targeting emerging indications such as heart failure or oncology.
• Partnerships: Strengthen collaborations with hospital networks and health authorities.
• Pricing Strategy: Balance competitive pricing with maintaining margins through value-based agreements.

---

Key Takeaways

• Pharmacosmos is positioned as a leading provider of high-dose IV iron therapies, with a focus on hospital and nephrology markets.
• Its product differentiation and regulatory progress give it a competitive edge but face challenges from entrenched competitors.
• Expansion into emerging markets and indication expansion are critical to future growth.
• Strategic collaboration and pipeline innovation will influence market positioning and share expansion.

---

FAQs

1. What distinguishes Pharmacosmos’s FDI from other IV iron therapies?
FDI allows for high-dose, single infusion treatments, reducing hospital visits and infusion sessions, with a safety profile supported by clinical trials.

2. How has regulatory approval impacted Pharmacosmos’s market expansion?
FDA approval in 2022 enables entry into the North American market, with subsequent regional approvals expected to deepen market presence.

3. What are the main competitive threats facing Pharmacosmos?
Dominance by existing players with established brands, biosimilar entry, regulatory delays, and pricing pressures.

4. Which markets offer the highest growth opportunities for Pharmacosmos?
North America, Japan, China, and emerging regions with high CKD and anemia prevalence.

5. What strategic moves should Pharmacosmos consider to strengthen its position?
Focus on pipeline development, entering new indications, expanding geographical approvals, and forming strategic partnerships.

---

References

[1] European Medicines Agency. (2022). Summary of Product Characteristics: Ferinject.
[2] U.S. Food and Drug Administration. (2022). FDA approves Ferric derisomaltose for iron deficiency anemia.
[3] MarketWatch. (2022). Global IV Iron Market Size, Share & Trends Analysis.
[4] Vifor Pharma. (2022). Annual Report 2022.
[5] Pharmacosmos. (2023). Corporate Presentation.